Integrated clinical genomics: New horizon for diagnostic and biomarker discoveries in cancer

Expert Review of Molecular Diagnostics

Volumn 13, Issue 1, 2013, Pages 1-4

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

breast cancer; colorectal cancer; copy number changes; genome sequencing; heterogeneity; integrated analysis; mutations; transcriptomics

Indexed keywords

TRANSCRIPTOME; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; COLORECTAL CANCER; GENE SEQUENCE; GENOMICS; HUMAN; MICROARRAY ANALYSIS; NEOPLASM; REVIEW;

BREAST NEOPLASMS; CHROMOSOME MAPPING; COLORECTAL NEOPLASMS; FEMALE; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; TUMOR MARKERS, BIOLOGICAL;

EID: 84871555703     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.132     Document Type: Review

References (20)

1. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17(3), 297-303 (2011).
2. Stephens PJ, Tarpey PS, Davies H et al.; Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403), 400-404 (2012).
3. Ellis MJ, Ding L, Shen D et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403), 353-360 (2012).
4. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403), 405-409 (2012).
5. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403), 395-399 (2012).
6. Curtis C, Shah SP, Chin SF et al.; METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346-352 (2012).
7. Ross-Innes CS, Stark R, Teschendorff AE et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381), 389-393 (2012).
8. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330-337 (2012).
9. Seshagiri S, Stawiski EW, Durinck S et al. Recurrent R-spondin fusions in colon cancer. Nature 488(7413), 660-664 (2012).
10. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).
11. Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices 7(6), 723-726 (2010).
12. Ecker JR, Bickmore WA, Barroso I, Pritchard JK, Gilad Y, Segal E. Genomics: ENCODE explained. Nature 489(7414), 52-55 (2012).
13. Pennisi E. Genomics. ENCODE project writes eulogy for junk DNA. Science 337(6099), 1159-1161 (2012).
14. Gerstein MB, Kundaje A, Hariharan M et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489(7414), 91-100 (2012).
15. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
16. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 11(2), 81-92 (2011).
17. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12(1), 56-68 (2011).
18. Roukos DH. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Expert Rev. Proteomics 9(4), 349-353 (2012).
19. Camacho DF, Pienta KJ. Disrupting the networks of cancer. Clin. Cancer Res. 18(10), 2801-2808 (2012).
20. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol. 8(2), e1002375 (2012).